Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Acyclovir vs Cryotherapy for Plantar Warts
NCT06261684Phase 3Recruiting
- Sponsor
- Cairo University
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aciclovir in plantar wart (2 arms), sponsored by Cairo University. Primary endpoints: Cure rate at 10 weeks, Recurrence rate at 24 weeks and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
aciclovir
03
Conditions
plantar wart
Beyond the preview
Go deeper on NCT06261684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261684.